The aim of this communication is to provide information regarding the use of antithyroid drugs (ATD) during lactation. Three ATD are used today: propylthiouracil (PTU), methimazole (MMI) and carbimazole (CMZ). The latter is a prodrug which is bioactivated to MMI. PTU is transferred in small amounts (0.025%) into milk. These amounts were considered nonsignificant for inducing adverse effects for the suckling infant. The amount of MMI excreted in milk is equal to MMI levels in serum. Due to its lower concentrations in milk, PTU was used for decades as the treatment of choice during breastfeeding. Recent studies have demonstrated that physical development, intelligence scores and thyroid status of children whose mothers had received MMI while breastfeeding were similar to those of healthy children. These new data offered clinicians an alternative drug approach. Several hepatic dysfunction studies have been published so far. Clinical manifestations varied from mild to severe hepatic failure, liver transplantation or death. Most PTU cases were more severe, idiosyncratic and not dose related. We recommend that PTU should not be prescribed for thyrotoxicosis during lactation. MMI should be used instead, in doses up to 30 mg/day, while PTU should be used in special cases for a restricted time period.

1.
Gartner LM, Morton J, Lawrence RA, Naylor AJ, O’Hare D, Schanler RJ, Eidelman AI: American Academy of Pediatrics Section on Breastfeeding: breastfeeding and the use of human milk. Pediatrics 2005;115:496–506.
2.
World Health Organization: Global Strategy for Infant and Young Child Feeding. Geneva, WHO, 2002.
3.
Chen A, Rogan WJ: Breastfeeding and the risk of postneonatal death in the United States. Pediatrics 2004;113:e435–e439.
4.
Ito S: Drug therapy for breast-feeding women. N Engl J Med 2000;343:118–126.
5.
Amino N, Tada H, Hidaka Y: The spectrum of postpartum thyroid dysfunction: diagnosis, management and long-term prognosis. Endocr Pract 1996;2:406–410.
6.
Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905–917.
7.
Farwell AP, Braverman LE: Thyroid and antithyroid drugs; in Hardman JG, Limbird LE, Gilman AG (eds): Goodmans and Gilman’s the Pharmacological Basis of Therapeutics, ed 10. New York, McGraw-Hill, 2001, pp 1563–1596.
8.
Jansson R, Dahlberg PA, Lindström B: Comparative bioavailability of carbimazole and methimazole. Int J Clin Pharmacol Ther Toxicol 1983;21:505–510.
9.
Wilson JT, Brown RD, Cherek DR, Dailey JW, Hilman B, Jobe PC, Manno BR, Manno JE, Redetzki HM, Stewart JJ: Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980;5:1–66.
10.
Kampmann JP, Johansen K, Hansen JM, Helweg J: Propylthiouracil in human milk. Revision of a dogma. Lancet 1980;i:736–737.
11.
Low LC, Lang J, Alexander WD: Excretion of carbimazole and propylthiouracil in breast milk. Lancet 1979;ii:1011.
12.
Johansen K, Andersen AN, Kampmann JP, Mølholm Hansen JM, Mortensen HB: Excretion of methimazole in human milk. Eur J Clin Pharmacol 1982;23:339–341.
13.
Cooper DS, Bode HH, Nath B, Saxe V, Maloof F, Ridgway EC: Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984;58:473–479.
14.
Goldman JM: Propylthiouracil and breast-feeding. CMAJ 1987;137:701–702.
15.
American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. Pediatrics 1989;84:924–936.
16.
Hale TW, Ilett KF: Drug Therapy and Breastfeeding: From Theory to Clinical Practice. New York, Parthenon Publishing Group, 2002.
17.
Azizi F: Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants. J Pediatr 1996;128:855–858.
18.
Azizi F, Hedayati M: Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest 2002;25:493–496.
19.
Azizi F: Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. J Endocrinol Invest 2003;26:301–304.
20.
Lamberg BA, Ikonen E, Osterlund K, Teramo K, Pekonen F, Peltola J, Välimäki M: Antithyroid treatment of maternal hyperthyroidism during lactation. Clin Endocrinol (Oxf) 1984;21:81–87.
21.
Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92(suppl 8):1–47.
22.
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA: Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727–1733.
23.
Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R: The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001;96:165–169.
24.
Lian XL, Bai Y, Dai WX, Jin ZM, Zeng ZP, Guo ZS: The clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism. Zhonghua Nei Ke Za Zhi 2004;43:442–446.
25.
Rivkees SA, Mattison DR: Propylthiouracil (PTU)-induced liver failure and recommendations for the discontinuation of PTU use in children. Int J Pediatr Endocrinol 2009;2009:132041.
26.
Krassas GE, Poppe K, Glinoer D: Thyroid function and human reproductive health. Endocr Rev 2010;31:702–755.
27.
Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN: The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673–674.
28.
US Food and Drug Administration: Information for Healthcare Professionals – Propylthiouracil-Induced Liver Failure. [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm].
29.
Karras S, Tzotzas T, Krassas GE: Antithyroid drugs used in the treatment of hyperthyroidism during breastfeeding: an update and new perspectives. Hormones (Athens) 2009;8:254–257.
30.
Karras S, Tzotzas T, Kaltsas T, Krassas GE: Pharmacological treatment of hyperthyroidism during lactation: review of the literature and novel data. Pediatr Endocrinol Rev 2010;8:25–33.
31.
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W: Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081–1125.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.